Janux Therapeutics and Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors January 25, 2026
Ph 1/2 Program Initiated for Elraglusib in refractory melanoma and additional target solid tumor and heme cancers January 25, 2026
MediLink Therapeutics and Roche to develop and commercialize YL201 across numerous solid tumor types January 18, 2026
Summit Therapeutics and GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 ADC January 18, 2026
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop RC148 for Advanced Solid Tumors January 18, 2026
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class ADCs for Hard-to-Treat Cancers January 18, 2026
IND application submitted for GTB-5550 TriKE for B7-H3 expressing solid tumor cancers January 18, 2026
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development January 11, 2026
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration January 11, 2026
Regulatory Clearances of IND Applications for CR-001 & CR-003 for the Treatment of Solid Tumors Announced January 11, 2026
FDA Clears IND for A2B543 for Mesothelin-expressing Solid Tumors lacking HLA-A*02 Expression January 11, 2026
Insilico Medicine Announces US$888M Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology January 4, 2026
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates January 4, 2026
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly January 4, 2026
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Gen Radionuclide Drug Conjugates December 30, 2025
